Paul Fredlund

Biography

Dr. Paul Fredlund has worked in clinical drug development designing and monitoring clinical trials in erectile dysfunction, diabetes, sepsis, Chron’s Disease, Non-Hodgkin’s Lymphoma and lung cancer. He has extensive experience drafting clinical study reports, preparing regulatory documents and evaluating potential in-licensing opportunities. He has a special interest in clinical drug safety (pharmacovigilance) and has served on several drug safety monitoring committees. In 2000 he joined ICOS Corporation and as Director; Clinical Research was actively involved in the clinical development and the successful worldwide registration of Cialis (tadalafil) for erectile dysfunction. In 2003/2004 Dr Fredlund was the Co-director of the Lilly/ICOS U.S. Affiliate Cialis™ Product Development Team responsible for the commercialization of Cialis and the design and implementation of Phase 4 Cialis clinical trials. Dr Fredlund graduated from Harvard College and Harvard Medical School. He completed his training with a residency in internal medicine at Harvard Medical School’s Peter Bent Brigham Hospital and a clinical fellowship in endocrinology and metabolism at the National Institutes of Health. He is board certified in internal medicine and endocrinology and has been a Clinical Professor of Medicine at the University of Washington School of Medicine.

Research Interest

His research interests are in Internal Medicine